These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 26831667)
1. Kaempferol inhibits cell proliferation and glycolysis in esophagus squamous cell carcinoma via targeting EGFR signaling pathway. Yao S; Wang X; Li C; Zhao T; Jin H; Fang W Tumour Biol; 2016 Aug; 37(8):10247-56. PubMed ID: 26831667 [TBL] [Abstract][Full Text] [Related]
2. Isoliquiritigenin Suppressed Esophageal Squamous Carcinoma Growth by Blocking EGFR Activation and Inducing Cell Cycle Arrest. Ye L; Zhang J; Zhang Y; Gu B; Zhu H; Mao X Biomed Res Int; 2020; 2020():9259852. PubMed ID: 32190688 [TBL] [Abstract][Full Text] [Related]
3. Butein Inhibited In Vitro Hexokinase-2-Mediated Tumor Glycolysis in Hepatocellular Carcinoma by Blocking Epidermal Growth Factor Receptor (EGFR). Liao W; Liu J; Zhang D; Huang W; Chen R Med Sci Monit; 2018 May; 24():3283-3292. PubMed ID: 29777095 [TBL] [Abstract][Full Text] [Related]
4. Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling pathway and epidermal growth factor receptor. Zhang Z; Guo Y; Chen M; Chen F; Liu B; Shen C Inflammopharmacology; 2021 Oct; 29(5):1587-1601. PubMed ID: 34322786 [TBL] [Abstract][Full Text] [Related]
5. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma. Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738 [TBL] [Abstract][Full Text] [Related]
6. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab. Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413 [TBL] [Abstract][Full Text] [Related]
7. Chrysin inhibited tumor glycolysis and induced apoptosis in hepatocellular carcinoma by targeting hexokinase-2. Xu D; Jin J; Yu H; Zhao Z; Ma D; Zhang C; Jiang H J Exp Clin Cancer Res; 2017 Mar; 36(1):44. PubMed ID: 28320429 [TBL] [Abstract][Full Text] [Related]
8. Isoalantolactone Inhibits Esophageal Squamous Cell Carcinoma Growth Through Downregulation of MicroRNA-21 and Derepression of PDCD4. Wen SW; Zhang YF; Li Y; Xu YZ; Li ZH; Lü H; Zhu YG; Liu ZX; Tian ZQ Dig Dis Sci; 2018 Sep; 63(9):2285-2293. PubMed ID: 29781054 [TBL] [Abstract][Full Text] [Related]
9. Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells. Yoshioka M; Ohashi S; Ida T; Nakai Y; Kikuchi O; Amanuma Y; Matsubara J; Yamada A; Miyamoto S; Natsuizaka M; Nakagawa H; Chiba T; Seno H; Muto M J Exp Clin Cancer Res; 2017 Aug; 36(1):101. PubMed ID: 28764725 [TBL] [Abstract][Full Text] [Related]
10. Capsaicin inhibits glycolysis in esophageal squamous cell carcinoma by regulating hexokinase‑2 expression. Mao X; Zhu H; Luo D; Ye L; Yin H; Zhang J; Zhang Y; Zhang Y Mol Med Rep; 2018 Apr; 17(4):6116-6121. PubMed ID: 29436634 [TBL] [Abstract][Full Text] [Related]
11. Dexrazoxane inhibits the growth of esophageal squamous cell carcinoma by attenuating SDCBP/MDA-9/syntenin-mediated EGFR-PI3K-Akt pathway activation. Du R; Xiao N; Han L; Guo K; Li K; Chen Z; Zhang H; Zhou Z; Huang Y; Zhao X; Bian H Sci Rep; 2024 Apr; 14(1):9167. PubMed ID: 38649770 [TBL] [Abstract][Full Text] [Related]
12. Galectin-3 knockdown increases gefitinib sensitivity to the inhibition of EGFR endocytosis in gefitinib-insensitive esophageal squamous cancer cells. Cui G; Cui M; Li Y; Liang Y; Li W; Guo H; Zhao S Med Oncol; 2015 Apr; 32(4):124. PubMed ID: 25788032 [TBL] [Abstract][Full Text] [Related]
13. Licochalcone A suppresses hexokinase 2-mediated tumor glycolysis in gastric cancer via downregulation of the Akt signaling pathway. Wu J; Zhang X; Wang Y; Sun Q; Chen M; Liu S; Zou X Oncol Rep; 2018 Mar; 39(3):1181-1190. PubMed ID: 29286170 [TBL] [Abstract][Full Text] [Related]
14. Cetuximab inhibits cisplatin-induced activation of EGFR signaling in esophageal squamous cell carcinoma. Kwon J; Yoon HJ; Kim JH; Lee TS; Song IH; Lee HW; Kang MC; Park JH Oncol Rep; 2014 Sep; 32(3):1188-92. PubMed ID: 24993015 [TBL] [Abstract][Full Text] [Related]
15. Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models. Hou W; Qin X; Zhu X; Fei M; Liu P; Liu L; Moon H; Zhang P; Greshock J; Bachman KE; Ye BC; Wang H; Zang CY Oncol Rep; 2013 Aug; 30(2):707-14. PubMed ID: 23708506 [TBL] [Abstract][Full Text] [Related]
16. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest. Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693 [TBL] [Abstract][Full Text] [Related]
17. Pterostilbene suppresses the growth of esophageal squamous cell carcinoma by inhibiting glycolysis and PKM2/STAT3/c-MYC signaling pathway. Yang Y; Li S; Shi W; Jin G; Guo D; Li A; Wang B; Lu B; Feng S Int Immunopharmacol; 2024 Dec; 142(Pt B):113247. PubMed ID: 39321706 [TBL] [Abstract][Full Text] [Related]
18. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion. Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194 [TBL] [Abstract][Full Text] [Related]
19. A multi-kinase inhibitor APG-2449 enhances the antitumor effect of ibrutinib in esophageal squamous cell carcinoma via EGFR/FAK pathway inhibition. Luo QY; Zhou SN; Pan WT; Sun J; Yang LQ; Zhang L; Qiu MZ; Yang DJ Biochem Pharmacol; 2021 Jan; 183():114318. PubMed ID: 33159967 [TBL] [Abstract][Full Text] [Related]
20. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo. Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]